Methodology of cognitive impairment assessment in depressive disorder
Authors:
S. Fedorová; E. Bartečků; J. Hořínková
Authors place of work:
Psychiatrická klinika LF MU a FN Brno
Published in the journal:
Cesk Slov Neurol N 2020; 83(1): 43-47
Category:
Review Article
doi:
https://doi.org/10.14735/amcsnn202043
Summary
This review article summarizes current information about cognitive impairment present in most of the patients with major depression. Cognitive impairment could be considered as one of the primary group of symptoms of depressive disorder and is one of the main factors in functional impairment in this patient population. Cognitive dysfunction affects more cognitive domains, is heterogeneous and is both subjective and objective. These facts complicate basic screening. There is no widely accepted consensus in the choice of test methods and in guidelines on cognitive assessment in depressive disorder. Tests which are mostly used for cognitive assessment in depressive disorder, were not created for this patient population. Moreover, basic screening methods such as Mini Mental State Examination (MMSE), Addenbrooke Cognitive Examination (ACE-R), or Montreal Cognitive Assessment (MoCA) are not sufficient in their sensitivity and specificity. Tests which appear more suitable in this disorder are those measuring cognitive domains most affected in depressive disorder – especially episodic memory, executive functions and processing speed. Test methods developed primarily for patients with a depressive disorder are University of California San Diego Performance-Based Skills Assessment (UPSA), THINC-Integrated Tool (THINC-it) and Screen for Cognitive Impairment in Psychiatry-Depression (SCI-P). Further research should address mostly systematic screening and assessment of cognitive impairment specific for depressive disorder and its changes.
Keywords:
depressive disorder – cognitive dysfunction – psychological tests
Zdroje
1. World Health Organization. Depression and other common mental disorders: global health estimates 2017. [online]. Available from URL: http:/ / apps.who.int/ iris/ bitstream/ 10665/ 254610/ 1/ WHO-MSD-MER-2017.2-eng.pdf.
2. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013; 34: 119–138. doi: 10.1146/ annurev-publhealth-031912-114409.
3. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386(9995): 743–800. doi: 10.1016/ S0140-6736(15)60692-4.
4. Hammar A, Ardal G. Cognitive functioning in major depression – a summary. Front Hum Neurosci 2009; 3(26): 1–7. doi: 10.3389/ neuro.09.026.2009.
5. Marazziti D, Consoli G, Picchetti M et al. Cognitive impairment in major depression. Eur J Pharmacol 2010; 626(1): 83–86. doi: 10.1016/ j.ejphar.2009.08.046.
6. Roiser JP, Elliott R, Sahakian BJ. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology 2012; 37(1): 117–136. doi: 10.1038/ npp.2011.183.
7. Gonda X, Pompili M, Serafini G et al. The role of cognitive dysfunction in the symptoms and remission from depression. Ann Gen Psychiatry 2015; 14: 27. doi: 10.1186/ s12991-015-0068-9.
8. Baune BT, Air T. Clinical, functional, and biological correlates of cognitive dimensions in major depressive disorder – rationale, design, and characteristics of the cognitive function and mood study (CoFaM-Study). Front Psychiatry 2016; 7: 150. doi: 10.3389/ fpsyt.2016.00150.
9. Airaksinen E, Wahlin A, Forsell Y et al. Low episodic memory performance as a premorbid marker of depression: evidence from a 3-year follow-up. Acta Psychiatr Scand 2007; 115(6): 458–465. doi: 10.1111/ j.1600-0447.2006.00932.x.
10. Clark M, DiBenedetti D, Perez V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res 2016; 16(4): 455–463. doi: 10.1080/ 14737167.2016.1195688.
11. Fried EI, Nesse RM. The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS One 2014; 9(2): e90311. doi: 10.1371/ journal.pone.0090311.
12. Richard-Devantoy S, Ding Y, Lepage M et al. Cognitive inhibition in depression and suicidal behavior: a neuroimaging study. Psychol Med 2016; 46(5): 933–944. doi: 10.1017/ S0033291715002421.
13. Weightman MJ, Air TM, Baune BT. A review of the role of social cognition in major depressive disorder. Front Psychiatry 2014; 5: 179. doi: 10.3389/ fpsyt.2014.00179.
14. Skokou M, Soubasi E, Gourzis P. Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol 2012; 2012: 427102. doi: 10.5402/ 2012/ 427102.
15. Leyhe T, Reynolds CF 3rd et al. A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. Alzheimers Dement 2017; 13(1): 59–71. doi: 10.1016/ j.jalz.2016.08.007.
16. Kessing LV, Andersen PK. Evidence for clinical progression of unipolar and bipolar disorders. Acta Psychiatr Scand 2017; 135(1): 51–64. doi: 10.1111/ acps.12667.
17. Ragguett RM, Cha DS, Kakar R et al. Assessing and measuring cognitive function in major depressive disorder. Evid Based Ment Health 2016; 19(4): 106–109. doi: 10.1136/ eb-2016-102456.
18. Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr 2013; 18(3): 139–149. doi: 10.1017/ S1092852913000072.
19. Ott CV, Bjertrup AJ, Jensen JH et al. Screening for cognitive dysfunction in unipolar depression: validation and evaluation of objective and subjective tools. J Affect Disord 2016; 190: 607–615. doi: 10.1016/ j.jad.2015.10.059.
20. Motter JN, Pimontel MA, Rindskopf D et al. Computerized cognitive training and functional recovery in major depressive disorder: a meta-analysis. J Affect Disord 2016; 189: 184–191. doi: 10.1016/ j.jad.2015.09.022.
21. Lee RSC, Hermens DF, Porter MA et al. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord 2012; 140(2): 113–124. doi: 10.1016/ j.jad.2011.10.023.
22. Wagner KD, Asarnow JR, Vitiello B et al. Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. J Child Adolesc Psychopharmacol 2012; 22(1): 5–10. doi: 10.1089/ cap.2011.0045.
23. Habert J, Katzman MA, Oluboka OJ et al. Functional recovery in major depressive disorder: focus on early optimized treatment. Prim Care Companion CNS Disord 2016; 18(5). doi: 10.4088/ PCC.15r01926.
24. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2011; 41(6): 1165–1174. doi: 10.1017/ S0033291710001911.
25. McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr 2015; 20 (Suppl 1): 20–30. doi: 10.1017/ S1092852915000826.
26. Russo M, Mahon K, Burdick KE. Measuring cognitive functions in MDD: emerging assessment tools. Depress Anxiety 2015; 32(4): 262–269. doi: 10.1002/ da.22297.
27. McIntyre RS, Soczynska JZ, WoldeyohannesHO et al. The impact of cognitive im-pairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry 2015; 56: 279–282. doi: 10.1016/ j.comppsych.2014.08.051.
28. Davis MT, DellaGioia N, Matuskey D et al. Preliminary evidence concerning the pattern and magnitude of cognitive dysfunction in major depressive disorder using cogstate measures. J Affect Disord 2017; 218: 82–85. doi: 10.1016/ j.jad.2017.04.064.
29. McIntyre RS, Lee Y, Carmona NE et al. Characterizing, assessing, and treating cognitive dysfunction in major depressive disorder. Harv Rev Psychiatry 2018; 26(5): 241–249. doi: 10.1097/ HRP.0000000000000171.
30. Zuckerman H, Pan Z, Park C et al. Recognition and treatment of cognitive dysfunc-tion in major depressive disorder. Front Psychiatry 2018; 9: 655. doi: 10.3389/ fpsyt.2018.00655.
31. Rajji TK, Miranda D, Mulsant BH et al. The MMSE is not ad adequate screening cognitive instrument in studies of late-life depression. J Psychiatr Res 2009; 43(4): 464–470. doi: 10.1016/ j.jpsychires.2008.06.002.
32. McClintock SM, Cullum M, Husain MM et al. Evaluation of the effects of severe depression on global cognitive function and memory. CNS Spectr 2010; 15(5): 304–313. doi: 10.1017/ s109285290002753x.
33. Harrison, JE. Detecting and measuring cognitive change. In: McIntyre RS, Cha DS (eds). Cognitive impairment in major depressive disorder. Clinical relevance, biological substrates, and treatment opportunities. 1st ed. Cambridge: Cambridge University Press 2016: 233–237.
34. Papakostas GI, Culpepper L. Understanding and managing cognition in the depressed patients. J Clin Psychiatry 2015; 76(4): 418–425. doi: 10.4088/ JCP.13086ah1c.
35. Fiorillo A, Carpiniello B, De Giorgi S et al. Assessment and management of cognitive and psychosocial dysfunctions in patients with major depressive disorder: A clinical review. Front Psychiatry 2018; 9: 493. doi: 10.3389/ fpsyt.2018.00493.
36. Strober LB, Binder A, Nikelshpur OM et al. The perceived deficits questionnaire: perception, deficit, or di-stress? Int J MS Care 2016; 18(4), 183–190. doi: 10.7224/ 1537-2073.2015-028.
37. Naismith SL, Longley WA, Scott EM et al. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry 2007; 7: 32. doi: 10.1186/ 1471-244X-7-32.
38. Keefe RS, McClintock SM, Roth RM et al. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J Clin Psychiatry 2014; 75(8): 864–876. doi: 10.4088/ JCP.13r08609.
39. Sommerfeldt SL, Cullen KR, Han G et al. Executive attention impairment in adolescents with major depressive disorder. J Clin Child Adolesc Psychol 2016; 45(1): 69–83. doi: 10.1080/ 15374416.2015.1072823.
40. McIntyre RS, Cha DS, Soczynska JK et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 2013; 30(6): 515–527. doi: 10.1002/ da.22063.
41. Věchetová G, Bolceková E et al. Měření kognitivních funkcí pomocí krátkých opakovatelných neuropsychologických baterií. Cesk Slov Neurol N 2018; 81/ 114(1): 29–36. doi: 10.14735/amcsnn201829.
Štítky
Paediatric neurology Neurosurgery NeurologyČlánok vyšiel v časopise
Czech and Slovak Neurology and Neurosurgery
2020 Číslo 1
- Memantine Eases Daily Life for Patients and Caregivers
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Metamizole vs. Tramadol in Postoperative Analgesia
Najčítanejšie v tomto čísle
- Neonatal seizures – current view of the issue
- Possible prevention of Alzheimer’s disease
- The primary Non-Hodgkin’s central nervous system lymphoma
- Neuropsychiatric symptoms as early manifestation of Alzheimer’s disease